In summary, CIM7, which we identified based on rational targeting of the NCoR1/RARα interaction, is a first-in-class selective CMA inhibitor capable of potently inhibiting CMA in nanomolar concentrations through transcriptional regulation of key CMA components in NSCLC and not in non-tumorigenic cell lines. This evidence concerns the gene NCOR1 and non-small cell lung carcinoma.